Alabama Administrative Code
Title 540 - ALABAMA BOARD OF MEDICAL EXAMINERS
Chapter 540-X-26 - COLLABORATIVE PHARMACY PRACTICE
Section 540-X-26-.01 - Definitions
Universal Citation: AL Admin Code R 540-X-26-.01
Current through Register Vol. 42, No. 11, August 30, 2024
(1) The following definitions are applicable to collaborative drug therapy management:
(a) "Agreement" means the Collaborative Drug
Therapy Management Agreement.
(b)
"Board of Medical Examiners" means the State Board of Medical Examiners
established pursuant to Ala. Code §
34-24-53.
(c) "Board of Pharmacy" means the State Board
of Pharmacy established pursuant to Ala. Code §
34-23-90.
(d) "Collaborative Drug Therapy Management"
means the practice of pharmacy whereby an individual pharmacist licensed in
this state jointly and voluntarily works with an individual physician licensed
in this state under a Collaborative Drug Therapy Management Agreement to
provide a range of services to a patient of the Collaborating Physician and the
Collaborating Pharmacist intended to optimize therapeutic outcomes; detect and
prevent adverse medication interactions and side effects; provide education on
the patient's medications used to treat the disease state so that medications
are taken correctly; monitor, modify, and discontinue drug therapy as directed
by the physician; provide education on managing medication side effects;
communicate with third party payors and insurers regarding prior authorization
for prescription medications; and any other activity or service specified in a
protocol approved by both the Board of Medical Examiners and the Board of
Pharmacy, or otherwise authorized by this Chapter.
(e) "Collaborating Pharmacist" means a
pharmacist who is licensed to practice pharmacy in Alabama, who is a party to a
Collaborative Drug Therapy Management Agreement, and who has a direct
pharmacist-patient relationship with the patient served by the
Agreement.
(f) "Collaborating
Physician" means a doctor of medicine or a doctor of osteopathy licensed to
practice medicine in Alabama who is a party to a Collaborative Drug Therapy
Management Agreement, who has a direct physician-patient relationship, or
otherwise authorized by this Chapter, with the patient served by the Agreement,
and who has prepared the patient-specific, drug or drug class-specific,
disease-specific, and condition-specific plan of care based on a physical
examination of the patient where required under this Chapter.
(g) "Covering Pharmacist" means a pharmacist
licensed to practice pharmacy in Alabama who agrees in writing to be readily
available to fulfill the duties of a Collaborating Pharmacist pursuant to a
Collaborative Drug Therapy Management Agreement during the absence of the
Collaborating Pharmacist. The Covering Pharmacist shall be an employee of the
same pharmacy practice as the Collaborating Pharmacist, demonstrate the ability
to provide the services listed in the Agreement, and abide by the rules and
regulations of the Board of Medical Examiners and Board of Pharmacy.
(h) "Covering Physician" means a doctor of
medicine or a doctor of osteopathy licensed to practice medicine in Alabama who
agrees in writing to be readily available to fulfill the duties of a
Collaborating Physician pursuant to a Collaborative Drug Therapy Management
Agreement during the absence of the Collaborating Physician. The covering
physician shall be either a member of the same medical practice, practice
group, or multidisciplinary medical team, or of the same or similar practice
specialty as the Collaborating Physician and shall abide by the rules and
regulations adopted by the Board of Medical Examiners and Board of
Pharmacy.
(i) "Formulary" means a
list of legend drugs or drug classes that may be utilized under a Collaborative
Drug Therapy Management Agreement.
(j) "Joint Committee" means the Joint
Committee on Pharmacy Collaborative Practice, established for the purpose of
enabling a mechanism for the exchange of information between the Board of
Medical Examiners and the Board of Pharmacy on matters related to
physician-pharmacist collaboration.
(k) "Licensed Healthcare Facility" means a
hospital, as defined in Ala. Code §
22-21-20(1),
licensed by the Alabama Department of Public Health, or a Federally Qualified
Health Center, as defined by Ala. Admin. Code r.
560-X-48-.01(1).
(l) "Patient Care Services" means services
rendered by Collaborating Physicians and Collaborating Pharmacists for the
benefit of the patient and which must be within the professional training and
experience of the Collaborating Physician and Collaborating Pharmacist and be
covered by the Collaborative Drug Therapy Management Agreement.
(m) "Protocol" means a document approved by
the Board of Medical Examiners and Board of Pharmacy establishing the
permissible functions and activities to be performed by a Collaborating
Pharmacist and signed by the parties to the Collaborative Drug Therapy
Management Agreement.
(n) "Quality
Assurance" means documented evaluation by the Collaborating Physician of the
parties' adherence to the Agreement and patient outcomes against defined
quality outcome measures, using a selected, meaningful sample of patient
records, which will identify outcomes needing improvement, set performance
goals, and assess progress towards meeting established goals, with a summary of
findings, conclusions, and, if indicated, recommendations for change. The
physician's signature on the patient record does not constitute quality
assurance monitoring.
(o) "Routine
Scope of Practice and Services" means any patient care service provided by the
Collaborating Physician and his or her practice in compliance with his or her
medical education, training, experience, and the Board of Medical Examiners'
laws, rules, policies, and procedures, and that of the collaborating pharmacist
and his or her practice in compliance with his or her pharmacy education,
training, experience, and the Board of Pharmacy's laws, rules, policies, and
procedures.
(p) "Unrestricted," for
the purpose of this Chapter, means an active pharmacy permit, pharmacy Drug
Enforcement Administration (DEA) registration, pharmacist license, medical
license, and Alabama Controlled Substances Certificate that is not revoked,
suspended, or on probation at the time of application and is not subject to any
conditions, restrictions, or limitations imposed by the applicable licensing
board which relate directly to the delivery of health care services. A
condition, restriction, or limitation directly relates to the delivery of
health care services when it prevents a provider from treating certain types of
patients or certain types of ailments or injuries, or otherwise limits a
provider from fully engaging in the practice which would otherwise be
authorized pursuant to his or her license.
(q) "Acute, uncomplicated illness or injury"
means a recent or new short-term problem with low risk of morbidity for which
treatment is considered and full recovery without functional impairment is
expected. For the purposes of this section, and acute, uncomplicated illness or
injury includes:
(a) Influenza.
(b) Streptococcus.
(c) Any other condition as recommended by the
Joint Committee.
Under this definition, a pharmacist may use any tests which the Centers for Medicare and Medicaid Services has determined qualifies for a waiver under the federal Clinical Laboratory Improvement Amendments of 1988, or the federal rules adopted thereunder, or any established screening procedures that can safely be performed by a pharmacist.
Author: Alabama Board of Medical Examiners
Statutory Authority: Code of Ala. 1975, § 34-24-53; Act 2019-368 (Code of Ala. 1975, § 34-23-77).
Disclaimer: These regulations may not be the most recent version. Alabama may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.